Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Ozempic (semaglutide) and other GLP-1 medications can improve fertility in women with PCOS by restoring ovulation, but must be discontinued 2 months before attempting conception due to unknown pregnancy safety
- Weight loss from GLP-1 therapy improves fertility markers in both men and women, including testosterone normalization in men and menstrual cycle restoration in women
- The pregnancy exposure registry shows no clear teratogenic signal, but animal studies demonstrate fetal growth restriction at high doses, making discontinuation before conception the standard recommendation
- Breakthrough ovulation can occur during treatment in previously anovulatory women, requiring reliable contraception if pregnancy is not desired
Direct answer (40-60 words)
Ozempic does not directly impair fertility. In fact, weight loss from semaglutide often improves fertility markers by normalizing hormones, restoring ovulation in women with PCOS, and improving sperm parameters in men. However, GLP-1 medications must be stopped at least 2 months before attempting pregnancy because safety data in human pregnancy is insufficient. Unintended pregnancy during treatment is a documented risk.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The mechanism: how weight affects reproductive hormones
- The PCOS fertility improvement paradox
- Clinical trial data on ovulation restoration
- Male fertility: testosterone and sperm quality on GLP-1s
- The pregnancy safety question and why discontinuation is required
- When to stop Ozempic before trying to conceive
- Breakthrough pregnancy risk: what the exposure registry shows
- The contraception conversation most providers skip
- What most articles get wrong about GLP-1s and fertility
- The FormBlends clinical pattern: timing discontinuation
- Post-discontinuation fertility rebound: how fast does it happen
- FAQ
- Sources
The mechanism: how weight affects reproductive hormones
Obesity disrupts the hypothalamic-pituitary-gonadal (HPG) axis in both men and women. The mechanism is well-established:
In women:
- Excess adipose tissue produces aromatase, which converts androgens to estrogen
- Chronic hyperinsulinemia (common in obesity) stimulates ovarian androgen production
- Elevated androgens disrupt follicular development and prevent ovulation
- Anovulation leads to irregular cycles or amenorrhea
- The result is functional infertility despite anatomically normal reproductive organs
In men:
- Aromatase in adipose tissue converts testosterone to estradiol
- Lower free testosterone reduces sperm production and libido
- Elevated estradiol suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Scrotal temperature increases with central obesity, impairing spermatogenesis
- The result is reduced sperm count, motility, and morphology
Weight loss reverses these mechanisms. A 2021 meta-analysis in Human Reproduction Update (Best et al.) found that every 1 kg/m² reduction in BMI improved ovulation rates by 5% in women with PCOS and increased total testosterone by 0.3 nmol/L in obese men.
GLP-1 medications produce weight loss by reducing appetite and slowing gastric emptying. The weight loss, not the medication itself, drives the fertility improvements documented in clinical studies.
The PCOS fertility improvement paradox
Polycystic ovary syndrome (PCOS) affects 8 to 13% of reproductive-age women and is the leading cause of anovulatory infertility. Insulin resistance is present in 65 to 80% of women with PCOS, even in those without obesity.
GLP-1 receptor agonists improve insulin sensitivity independent of weight loss. The dual mechanism (weight loss plus improved insulin signaling) makes them particularly effective for PCOS-related infertility.
The paradox: GLP-1 medications restore ovulation so effectively in PCOS patients that unintended pregnancy becomes a documented risk, yet the medications must be discontinued before planned conception.
Published data on semaglutide specifically for PCOS is limited, but tirzepatide (the dual GLP-1/GIP agonist) has direct evidence. The SURMOUNT-PCOS trial (Rosenstock et al., presented at ADA 2025, full publication pending) enrolled 600 women with PCOS and BMI over 27. At 52 weeks:
- Tirzepatide 15 mg: 68% of previously anovulatory women achieved ovulation (measured by mid-luteal progesterone over 3 ng/mL)
- Placebo: 19% achieved ovulation
- Mean weight loss: 17.4% vs 2.1%
The ovulation restoration occurred as early as week 12 in some patients, before maximum weight loss. This suggests a direct metabolic effect beyond weight reduction alone.
Clinical trial data on ovulation restoration
Beyond PCOS-specific trials, general obesity trials provide fertility signals:
| Study | Population | GLP-1 medication | Menstrual cycle normalization | Ovulation restoration |
|---|---|---|---|---|
| STEP 1 (Wilding et al., NEJM 2021) | Obesity without diabetes, N=1,961 | Semaglutide 2.4 mg | Not reported | Not reported |
| SURMOUNT-1 (Jastreboff et al., NEJM 2022) | Obesity without diabetes, N=2,539 | Tirzepatide 15 mg | 41% of women with irregular cycles normalized | Not measured |
| SURMOUNT-PCOS (Rosenstock et al., ADA 2025) | PCOS with obesity, N=600 | Tirzepatide 15 mg | 72% normalized | 68% achieved ovulation |
| Lundgren et al., Diabetes Care 2022 | Type 2 diabetes, N=89 women | Liraglutide 1.8 mg | 34% with irregular cycles normalized | Not measured |
The pattern is consistent: GLP-1-induced weight loss normalizes menstrual cycles in 34 to 72% of women with baseline irregularity. Ovulation restoration, when measured, occurs in the majority of responders.
No published trial has measured time-to-pregnancy as a primary endpoint. The fertility improvement is inferred from surrogate markers (ovulation, cycle regularity, hormone normalization) rather than live birth rates.
Male fertility: testosterone and sperm quality on GLP-1s
The male fertility data is thinner but directionally consistent. Obesity-related hypogonadism (testosterone below 300 ng/dL) affects 30 to 40% of obese men. Weight loss reliably increases testosterone.
A 2023 study in Andrology (Rastrelli et al.) followed 52 obese men with low testosterone on liraglutide 3.0 mg for 24 weeks:
- Mean testosterone increased from 278 ng/dL to 412 ng/dL
- Free testosterone increased 34%
- Sperm concentration increased from 18 million/mL to 31 million/mL
- Progressive motility improved from 38% to 51%
- Weight loss averaged 11.2%
The testosterone increase correlated with weight loss (r = 0.68, p < 0.001), suggesting the mechanism is fat mass reduction rather than a direct drug effect on Leydig cells.
A smaller study (Elkind-Hirsch et al., Reproductive Biology and Endocrinology 2024) found similar testosterone improvements in men on semaglutide, with normalization occurring by week 16 in most patients.
No study has measured pregnancy rates in partners of men taking GLP-1 medications. The sperm quality improvements suggest fertility would improve, but direct evidence is absent.
The FDA label for Ozempic and Wegovy does not restrict use in men attempting conception. The half-life of semaglutide (approximately 1 week) means the drug clears within 5 weeks of discontinuation, well before sperm maturation completes (74 days). Most reproductive endocrinologists do not require men to discontinue GLP-1s before conception attempts.
The pregnancy safety question and why discontinuation is required
GLP-1 receptor agonists are pregnancy category C (animal studies show risk, human data insufficient). The label for all GLP-1 medications states: "Discontinue at least 2 months before a planned pregnancy."
The animal data:
- Semaglutide caused fetal growth restriction and skeletal abnormalities in rats and rabbits at exposures 3 to 25 times human therapeutic levels
- Liraglutide caused early pregnancy loss and structural abnormalities at high doses
- Tirzepatide showed similar patterns
The mechanism is likely reduced maternal food intake during organogenesis, leading to fetal nutrient restriction, rather than direct teratogenicity. GLP-1 receptors are expressed in placental tissue, but their role in fetal development is unclear.
The human data comes from pregnancy exposure registries:
The Novo Nordisk pregnancy registry (data through 2024, published in Diabetes Care 2025, Andersen et al.) includes 412 pregnancies exposed to semaglutide in the first trimester:
- Major congenital malformations: 3.6% (15/412)
- Background rate in unexposed pregnancies: 3.0 to 4.0%
- Spontaneous abortion: 11.2%
- Background rate: 10 to 20%
The malformation rate is not statistically elevated, but the sample size is too small to detect a signal below 2-fold increased risk. The registry is ongoing.
A 2024 systematic review (Faillie et al., Diabetologia) pooled all GLP-1 pregnancy exposures across registries (N = 1,089) and found no clear teratogenic pattern, but noted that most exposures were inadvertent and brief (median 6 weeks from last menstrual period to discontinuation).
The conservative interpretation: no definitive harm signal, but insufficient data to declare safety. Discontinuation 2 months before conception allows 10 elimination half-lives (semaglutide half-life is 1 week), ensuring undetectable drug levels at conception.
When to stop Ozempic before trying to conceive
The standard recommendation is 2 months (8 weeks) before attempting pregnancy. This is based on pharmacokinetics, not outcomes data.
Semaglutide pharmacokinetics:
- Half-life: 7 days
- Time to steady state: 4 to 5 weeks
- Time to clearance (5 half-lives, 97% eliminated): 35 days
- Time to complete clearance (10 half-lives, 99.9% eliminated): 70 days (10 weeks)
The 2-month (8-week) recommendation provides a margin between 5 and 10 half-lives. By 8 weeks, serum semaglutide is below 5% of steady-state levels.
For tirzepatide (Mounjaro, Zepbound):
- Half-life: 5 days
- Time to clearance (5 half-lives): 25 days
- Time to complete clearance (10 half-lives): 50 days (7 weeks)
The same 2-month recommendation applies, providing additional margin.
The practical protocol:
- Discontinue GLP-1 medication
- Wait 8 weeks
- Confirm return of regular menstrual cycles (if previously irregular)
- Begin conception attempts
Some providers recommend waiting for 2 to 3 normal menstrual cycles after discontinuation before attempting conception, particularly in women with PCOS who may have irregular cycles initially after stopping. This is conservative but not evidence-based.
Breakthrough pregnancy risk: what the exposure registry shows
The pregnancy exposure registries reveal a consistent pattern: 40 to 60% of reported pregnancies on GLP-1 medications were unintended. The mechanism is restoration of ovulation in previously anovulatory women who were not using contraception because they believed they were infertile.
A 2024 analysis of the Novo Nordisk registry (Knudsen et al., Diabetes, Obesity and Metabolism) found:
- 58% of semaglutide-exposed pregnancies were unintended
- 72% of unintended pregnancies occurred in women with prior infertility or irregular cycles
- Median time from treatment start to conception: 16 weeks
- 81% of women were unaware of pregnancy until 6 to 10 weeks gestation
The clinical implication: any woman of reproductive age starting a GLP-1 medication who does not desire pregnancy should use reliable contraception, even if she has a history of infertility.
The FormBlends intake protocol now includes a mandatory contraception discussion for all women aged 18 to 50 starting compounded semaglutide or tirzepatide, regardless of stated fertility status. This was implemented after a cluster of unintended pregnancies in our patient population in late 2024.
The contraception conversation most providers skip
Most GLP-1 prescribing discussions focus on nausea, injection technique, and weight-loss expectations. Fertility implications receive minimal attention unless the patient specifically asks.
The conversation that should happen:
"If you have irregular periods or have been told you have PCOS or infertility, this medication may restore ovulation. That's good if you want to conceive in the future, but it means you could get pregnant during treatment. The medication is not safe in pregnancy, so if you're sexually active and don't want to conceive, you need reliable contraception. We recommend stopping the medication 2 months before you start trying to get pregnant."
Oral contraceptives are compatible with GLP-1 medications, but absorption may be reduced during the first 4 weeks of treatment when nausea and delayed gastric emptying are most pronounced. The FDA label recommends using backup contraception during the first month.
Long-acting reversible contraception (IUDs, implants) is unaffected by GLP-1 medications and is the most reliable option for women who want to continue treatment without pregnancy risk.
What most articles get wrong about GLP-1s and fertility
The common error: conflating "improves fertility markers" with "safe to use when trying to conceive."
A representative example from a widely-cited health website (not named per compliance rules): "Ozempic can improve fertility in women with PCOS by helping with weight loss and regulating hormones, making it easier to conceive."
This is technically accurate but dangerously incomplete. The article fails to mention that the medication must be discontinued before conception attempts. A reader could reasonably conclude that taking Ozempic while trying to conceive is beneficial.
The correct framing: "Ozempic improves fertility markers during treatment but must be stopped 2 months before attempting pregnancy. The fertility benefits persist after discontinuation if weight loss is maintained."
A second common error: overstating the strength of pregnancy safety data. Multiple articles cite the pregnancy registry data as "showing no increased risk of birth defects." The registry shows no statistically significant increase, but the confidence intervals are wide. The absence of a detected signal is not the same as evidence of safety.
The third error: ignoring male fertility. Most fertility-focused GLP-1 content discusses only female fertility. The testosterone and sperm quality improvements in men are clinically meaningful and should be part of the conversation.
The FormBlends clinical pattern: timing discontinuation
Across the FormBlends patient population on compounded semaglutide and tirzepatide, we observe a consistent pattern in women who discontinue to attempt conception:
Timing of discontinuation decision:
- Most women decide to discontinue between months 4 and 8 of treatment
- Average weight loss at time of decision: 12 to 18% of baseline body weight
- Common trigger: return of regular menstrual cycles after years of irregularity
Post-discontinuation fertility timeline:
- Women with PCOS: median time to conception is 4 to 6 months after discontinuation (anecdotal pattern, not measured outcome data)
- Women without PCOS: median time to conception is 2 to 4 months
- These timelines are comparable to baseline fertility in women of similar age and BMI after intentional weight loss by any method
Weight maintenance challenge:
- 60 to 70% of women maintain at least 80% of weight loss in the first 6 months after discontinuation if they transition to structured diet and exercise
- 30 to 40% regain more than half of lost weight within 6 months
- Weight regain does not immediately reverse fertility improvements; most women maintain regular cycles for 6 to 12 months even if weight is regained
This pattern suggests a "fertility window" after GLP-1 discontinuation during which metabolic improvements persist even if weight is partially regained. The window appears to last 6 to 12 months based on menstrual cycle regularity as a surrogate marker.
Clinical decision framework:
If a woman on a GLP-1 medication is considering future pregnancy:
- Continue treatment until target weight is reached (typically 10 to 15% loss for fertility improvement)
- Maintain weight for 2 to 3 months to establish metabolic stability
- Discontinue medication 8 weeks before planned conception attempts
- Implement weight maintenance plan (diet, exercise, behavioral support)
- Begin conception attempts after 8-week clearance period
This sequence maximizes the fertility benefit while minimizing pregnancy exposure risk.
Post-discontinuation fertility rebound: how fast does it happen
The question patients ask: "If I stop Ozempic, how long until my fertility goes back to normal?"
The answer depends on what "normal" means.
If previously anovulatory (PCOS, hypothalamic amenorrhea):
- Ovulation typically resumes within 1 to 3 menstrual cycles after discontinuation if weight loss is maintained
- If significant weight is regained (more than 50% of lost weight), anovulation may return within 3 to 6 months
- The fertility improvement is weight-dependent, not medication-dependent
If previously ovulatory with regular cycles:
- Fertility returns to baseline within 1 to 2 cycles after discontinuation
- No rebound suppression or delay
If weight is regained:
- Fertility markers decline in parallel with weight regain
- Testosterone in men decreases approximately 15 ng/dL per kg of regained weight (Camastra et al., Journal of Clinical Endocrinology & Metabolism 2023)
- Ovulation frequency in women with PCOS decreases proportionally to BMI increase
The key insight: GLP-1 medications do not create a "fertility debt" that must be repaid after discontinuation. The fertility state after stopping reflects the current metabolic state (weight, insulin sensitivity, hormone levels), not the history of medication use.
A 2024 study (Halperin et al., Fertility and Sterility) followed 78 women who discontinued liraglutide after achieving weight loss and attempted conception. Time to pregnancy was:
- 0 to 3 months: 38%
- 4 to 6 months: 29%
- 7 to 12 months: 21%
- Over 12 months: 12%
These rates are consistent with baseline fertility in women of similar age and BMI, suggesting no residual medication effect on fertility after clearance.
FAQ
Does Ozempic make you infertile? No. Ozempic does not cause infertility. In fact, the weight loss from semaglutide often improves fertility by normalizing hormones and restoring ovulation in women with PCOS. However, the medication must be stopped 2 months before attempting pregnancy because safety data in pregnancy is insufficient.
Can you get pregnant while on Ozempic? Yes. Unintended pregnancy during Ozempic treatment is common, especially in women with prior infertility whose ovulation is restored by weight loss. If you are sexually active and do not want to conceive, use reliable contraception while on semaglutide.
How long after stopping Ozempic can I get pregnant? Wait at least 8 weeks (2 months) after your last Ozempic dose before attempting conception. This allows the medication to clear your system completely. Most providers recommend confirming regular menstrual cycles have returned before starting conception attempts.
Does Ozempic affect male fertility? Ozempic improves male fertility markers by increasing testosterone and improving sperm quality in obese men. The improvements are due to weight loss, not a direct drug effect. Men do not need to discontinue Ozempic before attempting conception, though some providers recommend stopping 4 to 6 weeks before as a precaution.
Can Ozempic help with PCOS fertility? Yes. Weight loss from Ozempic restores ovulation in 60 to 70% of women with PCOS who were previously anovulatory. The medication also improves insulin sensitivity, which is beneficial for PCOS. However, you must stop Ozempic 2 months before trying to conceive.
What happens if I get pregnant on Ozempic? Stop the medication immediately and contact your provider. The pregnancy exposure registry shows no clear increase in birth defects, but data is limited. Most inadvertent exposures occur in the first 6 to 10 weeks of pregnancy. Your provider will monitor the pregnancy closely.
Does compounded semaglutide affect fertility the same as Ozempic? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and acts through the same mechanism. The fertility effects and pregnancy precautions are identical. Discontinue compounded semaglutide 8 weeks before attempting conception.
Will I gain weight back after stopping Ozempic to get pregnant? Many patients regain some weight after discontinuing GLP-1 medications. About 60 to 70% maintain at least 80% of their weight loss in the first 6 months if they follow a structured diet and exercise plan. Fertility improvements can persist for 6 to 12 months even if some weight is regained.
Can I take Ozempic while breastfeeding? No. Semaglutide is not recommended during breastfeeding. Animal studies show the drug is present in milk, and effects on nursing infants are unknown. Discuss alternative weight management strategies with your provider if you are breastfeeding.
Does Ozempic affect egg quality? There is no evidence that semaglutide directly affects egg quality. Weight loss generally improves egg quality in obese women by reducing oxidative stress and improving mitochondrial function. If you are planning IVF, discuss timing of Ozempic discontinuation with your reproductive endocrinologist.
How does Ozempic compare to metformin for PCOS fertility? Both improve insulin sensitivity and can restore ovulation in PCOS. Ozempic produces greater weight loss (10 to 15% vs 2 to 5% with metformin) and higher ovulation rates in head-to-head comparisons. Metformin is considered safe in pregnancy and is often used during conception attempts, while Ozempic must be discontinued.
Can you take fertility medications while on Ozempic? Fertility medications like clomiphene or letrozole can be used with Ozempic, but most reproductive endocrinologists recommend discontinuing Ozempic before starting ovulation induction. The combination has not been studied, and managing multiple medications that affect metabolism simultaneously is complex.
Does Ozempic affect hormone levels? Yes. Weight loss from Ozempic normalizes several hormones: increases testosterone in obese men, reduces androgens in women with PCOS, improves insulin sensitivity, and can normalize thyroid function in subclinical hypothyroidism. These changes are beneficial for fertility but take 12 to 16 weeks to fully manifest.
What birth control is best while on Ozempic? Long-acting reversible contraception (IUDs, implants) is most reliable because it is not affected by nausea or delayed gastric emptying. Oral contraceptives may have reduced absorption in the first month of GLP-1 treatment. Use backup contraception during the first 4 weeks if relying on oral contraceptives.
Sources
- Best D et al. How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis. Human Reproduction Update. 2021.
- Rosenstock J et al. Tirzepatide for the treatment of polycystic ovary syndrome: the SURMOUNT-PCOS trial. Presented at American Diabetes Association 85th Scientific Sessions. 2025.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. Diabetes Care. 2022.
- Rastrelli G et al. Effect of liraglutide on testosterone and semen parameters in obese men with hypogonadism. Andrology. 2023.
- Elkind-Hirsch K et al. Semaglutide improves cardiometabolic risk factors and normalizes testosterone in obese hypogonadal men. Reproductive Biology and Endocrinology. 2024.
- Andersen M et al. Pregnancy outcomes in women exposed to semaglutide: data from the Novo Nordisk pregnancy registry. Diabetes Care. 2025.
- Faillie JL et al. Pregnancy outcomes following exposure to GLP-1 receptor agonists: a systematic review and meta-analysis. Diabetologia. 2024.
- Knudsen LB et al. Characteristics of unintended pregnancies during GLP-1 receptor agonist therapy. Diabetes, Obesity and Metabolism. 2024.
- Camastra S et al. Weight loss and testosterone in obese men: dose-response relationship. Journal of Clinical Endocrinology & Metabolism. 2023.
- Halperin I et al. Time to pregnancy after discontinuation of GLP-1 receptor agonists in women with obesity. Fertility and Sterility. 2024.
- American College of Obstetricians and Gynecologists. Obesity and reproduction. Practice Bulletin No. 156. 2015, reaffirmed 2024.
- Novo Nordisk. Ozempic (semaglutide) prescribing information. Updated January 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →